Brief: Candel Therapeutics Receives FDA Orphan Drug Designation For CAN-2409 For Treatment Of Pancreatic Cancer
11/04/2024 15:16
April 11 (Reuters) - Candel Therapeutics Inc CADL.O :
* CANDEL THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION
FOR
CAN-2409 FOR THE TREATMENT OF PANCREATIC CANCER
Source text for Eikon: ID:nGNX66Yf2J
Further company coverage: CADL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec